

Figure S1. Forest plot displaying the data from five included trials, revealing some asymmetry in the distribution of log hazard ratios.




Figure S2. Adverse event of cardiovascular disorders associated with second-generation FLT3 inhibitors compared to the control group. The relative weight indicates each study's contribution to the overall effect in the meta-analysis. FLT3, FMS-like tyrosine kinase 3.




Figure S3. Adverse event of anemia as an adverse event associated with second-generation FLT3 inhibitors compared to the control group. The relative weight indicates each study's contribution to the overall effect in the meta-analysis. FLT3, FMS-like tyrosine kinase 3.




Figure S4. Adverse event of neutropenia as an adverse event associated with second-generation FLT3 inhibitors compared to the control group. The relative weight indicates each study's contribution to the overall effect in the meta-analysis. FLT3, FMS-like tyrosine kinase 3.




Figure S5. Adverse event of thrombocytopenia as an adverse event associated with second-generation FLT3 inhibitors compared to the control group. The relative weight indicates each study's contribution to the overall effect in the meta-analysis. FLT3, FMS-like tyrosine kinase 3.




Figure S6. Adverse event of diarrhea as an adverse event associated with second-generation FLT3 inhibitors compared to the control group. The relative weight indicates each study's contribution to the overall effect in the meta-analysis. FLT3, FMS-like tyrosine kinase 3.




Figure S7. Adverse event of pneumonia as an adverse event associated with second-generation FLT3 inhibitors compared to the control group. The relative weight indicates each study's contribution to the overall effect in the meta-analysis. FLT3, FMS-like tyrosine kinase 3.




Figure S8. Summary of event-free survival effect of second-generation FLT3 inhibitors. The relative weight indicates each study's contribution to the overall effect in the meta-analysis. FLT3, FMS-like tyrosine kinase 3.

